drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically modified CAR T-cell therapy targeting mesothelin, engineered with CD28 costimulation, a tuned 1XX CD3ζ signaling domain to balance activation and persistence, and a PD-1 dominant-negative receptor to resist PD-1/PD-L1–mediated inhibition; delivered intraperitoneally for mesothelin-positive esophagogastric adenocarcinoma with peritoneal carcinomatosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Autologous T cells engineered to express a mesothelin-specific CAR with CD28 costimulation and a tuned 1XX CD3ζ signaling domain to balance activation and persistence, plus a PD‑1 dominant‑negative receptor that abrogates PD‑1/PD‑L1–mediated inhibition. Upon intraperitoneal delivery, the cells recognize mesothelin on tumor cells and execute cytotoxic killing and cytokine release while resisting checkpoint suppression.
drug_name
M28z1XXPD1DNR CAR
nct_id_drug_ref
NCT06623396